The Beacon

The Beacon episodes

September 03, 2017 Better Communication Leads to Better Outcomes for Cancer Patients (BMIC-004)
Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and the clinic lead to better clinical outcomes, including longer overall survival.
4 min
August 29, 2017 Are Two Immunotherapy Agents Better than One? Will the MYSTIC Trial Prove to Be a Mistake? (BMIC-003)
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in progression-free survival with an IT combination.
7 min
August 29, 2017 Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002)
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.
6 min
August 29, 2017 Importing Immunotherapy into the Curative Setting for NSCLC: The Potential Implications of the PACIFIC Trial (BMIC-001)
Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that the PACIFIC trial of durvalumab after chemo/radiation is positive for a significant improvement in progression-free survival.
5 min

From the publisher's feed

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.